Koyfin Home > Directory > Health Care > Amicus Therapeutics > Total Debt / (EBITDA-CAPEX)
View Chart On Koyfin
Cash and Short-Term Investments
Other Liabilities
Preferred Equity
Total Assets
Total Equity
Cash from Financing Activities
Cash from Investing Activities
Cash Flow from Operations
Levered Free Cash Flow (FCF)
Cash Acquisitions
Issuance of Common Stock
Repurchase of Common Stock
Debt Issued
Debt Repaid
Total Dividends Paid
Long-Term Debt
Long-Term Investments
Net Change in Cash
Gross Margin
Net Income Margin
Return on Assets %
Return on Capital %
Return on Equity %
Amicus Therapeutics Total Debt / (EBITDA-CAPEX) Chart (FOLD)
Amicus Therapeutics annual/quarterly Total Debt / (EBITDA-CAPEX) from 2009 to 2009.- Amicus Therapeutics Total Debt / (EBITDA-CAPEX) for the quarter ending December 12, 2009 was $0m
- Amicus Therapeutics Total Debt / Capital for the quarter ending September 09, 2018 was $44m a 27.22% increase of 12m year over year
- Amicus Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $39m a -4.44% decrease of -2m year over year
- Amicus Therapeutics Total Debt / Equity for the quarter ending September 09, 2018 was $78m a 39.91% increase of 31m year over year
Quarterly FOLD Total Debt / (EBITDA-CAPEX) Data
| 12/2009 | $0m |
Balance Sheet
Altman Z-scoreCash and Short-Term Investments
Other Liabilities
Preferred Equity
Total Assets
Total Equity
Cash Flow
Capital ExpendituresCash from Financing Activities
Cash from Investing Activities
Cash Flow from Operations
Levered Free Cash Flow (FCF)
Cash Acquisitions
Issuance of Common Stock
Repurchase of Common Stock
Debt Issued
Debt Repaid
Total Dividends Paid
Long-Term Debt
Long-Term Investments
Net Change in Cash
Margins & Efficiency
EBITDA MarginGross Margin
Net Income Margin
Return on Assets %
Return on Capital %
Return on Equity %